An observational study in Gout, Rheumatoid Arthritis and Sjogren's Syndrome, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by University Hospital, Strasbourg, France · Observational
Inflammatory rheumatic diseases affect 1% of the population. Treatment of such diseases should be based on disease activity, safety issues and other patient characteristics such as comorbidities (EULAR, 2022), leading to a higher risk of cardiovascular diseases. To this end, the general treat-to-target approach, as recommended in the EULAR guidance, may require several successive treatment lines based on updates to the patients' profile and close monitoring as the keystone of its implementation.
Regular feedback from patients could be used to fuel such strategies. This feedback can be collected using an ePRO (electronic Patient Reported Outcome). The purpose of this study is therefore to assess patient management using the information provided by patients through e-PROs, which will transfer the data provided by the patient to the physician and will notify the investigators via email when a patient has completed a form (no data interpretation or alerts).
The hypothesis is that the more physicians are provided with insights into their patients' health, the more they will function in a treat-to-target approach and the more often they will tend to adjust their patients' treatments.
345 studies on the registry are indexed under Gout; 49 are open to participants now.
This study's planned enrollment of 352 is above the median of 232 across 52 observational studies indexed under Gout.
Browse Gout studies →University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient with Gout, Rheumatoid arthritis, Sjogren's syndrome or Systemic lupus erythematosus
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with (at least) one of the following diseases:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Therapeutic management following access by the physician to his patient's ePROs
Behavioral: Therapeutic management following access by the physician to his patient's ePROs
Therapeutic management following access by the physician to his patient's ePROs
Frequency of therapeutic adjustments
To assess the relationship between the frequency of therapeutic adjustments over a 12-month period made by rheumatologists who were provided regular patient reported outcomes (PROs) and their use of an electronic platform providing them with these data.
Time frame: 12 months
Frequency of therapeutic adjustments
To assess the relationship between the frequency of therapeutic adjustments over a 6-month period made by rheumatologists who were provided regular patient reported outcomes (PROs) and their use of an electronic platform providing them with these data.
Time frame: 6 months
Frequency of therapeutic adjustments
To assess the relationship between the frequency of therapeutic adjustments over a 24-month period made by rheumatologists who were provided regular patient reported outcomes (PROs) and their use of an electronic platform providing them with these data.
Time frame: 24 months
Frequency of flares and exacerbation
To assess the fluctuation of disease activity and flares - as perceived by the patient
Time frame: Day 1
Frequency of flares and exacerbation
To assess the fluctuation of disease activity and flares - as perceived by the patient
Time frame: 6 months
Frequency of flares and exacerbation
To assess the fluctuation of disease activity and flares - as perceived by the patient
Time frame: 12 months
Frequency of flares and exacerbation
To assess the fluctuation of disease activity and flares - as perceived by the patient
Time frame: 24 months
RAPID 3 (Routine Assessment of Patient Index Data 3) questionnaire to measure the disease score
To assess the overall health of patients
Time frame: Day 1
RAPID 3 (Routine Assessment of Patient Index Data 3) questionnaire to measure the disease score
To assess the overall health of patients
Time frame: 6 months
RAPID 3 (Routine Assessment of Patient Index Data 3) questionnaire to measure the disease score
To assess the overall health of patients
Time frame: 12 months
RAPID 3 (Routine Assessment of Patient Index Data 3) questionnaire to measure the disease score
To assess the overall health of patients
Time frame: 24 months
HAQ score (Health Assessment Questionnaire) for health assessment
To assess the overall health of patients
Time frame: Day 1
HAQ score (Health Assessment Questionnaire) for health assessment
To assess the overall health of patients
Time frame: 6 months
HAQ score (Health Assessment Questionnaire) for health assessment
To assess the overall health of patients
Time frame: 12 months
HAQ score (Health Assessment Questionnaire) for health assessment
To assess the overall health of patients
Time frame: 24 months
IPAQ score (International Physical Activity Questionnaire) to measure physical activity
To assess patient's physical activity over time
Time frame: Day 1
IPAQ score (International Physical Activity Questionnaire) to measure physical activity
To assess patient's physical activity over time
Time frame: 6 months
IPAQ score (International Physical Activity Questionnaire) to measure physical activity
To assess patient's physical activity over time
Time frame: 12 months
IPAQ score (International Physical Activity Questionnaire) to measure physical activity
To assess patient's physical activity over time
Time frame: 24 months
PEPPI score (Perceived efficacy in patient-physician interactions)
To assess the patient-physician relationship
Time frame: 6 months
PEPPI score (Perceived efficacy in patient-physician interactions)
To assess the patient-physician relationship
Time frame: 12 months
PEPPI score (Perceived efficacy in patient-physician interactions)
To assess the patient-physician relationship
Time frame: 18 months
PEPPI score (Perceived efficacy in patient-physician interactions)
To assess the patient-physician relationship
Time frame: 24 months
Number of times patients logged in to the platform
To assess the use of the patient portal by patients and associated satisfaction
Time frame: 6 months
Number of times patients logged in to the platform
To assess the use of the patient portal by patients and associated satisfaction
Time frame: 12 months
Number of times patients logged in to the platform
To assess the use of the patient portal by patients and associated satisfaction
Time frame: 24 months
Number of times physicians logged in to the platform
To assess the viewing of patient-reported data by physicians
Time frame: 6 months
Number of times physicians logged in to the platform
To assess the viewing of patient-reported data by physicians
Time frame: 12 months
Number of times physicians logged in to the platform
To assess the viewing of patient-reported data by physicians
Time frame: 24 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →